Dingxiao Zhang

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

This study identifies VARS1 as a driver of prostate cancer progression by altering codon usage in translation, showing that targeting VARS1 can suppress tumor growth through dietary valine restriction or inhibitors.

This study identifies ERAD activity as a predictive and heritable marker of hematopoietic stem cell function by linking cytokine signaling to proteostasis remodeling.

In THP-1 cells, hypoxia drives Lyn-dependent YY1 phosphorylation and phase separation; YY1 and NUSAP1 SUMOylate and stabilize HIF-1α, and degrading YY1 curbs mouse prostate tumors.

This study identifies a hypoxic eIF1A+ luminal cell cluster in prostate cancer that promotes tumor progression and creates an immunosuppressive microenvironment, with potential therapeutic implications.

This study characterizes integrin family alterations across 32 cancer types, identifies integrinScore as a prognostic marker, and proposes potential therapeutic targets.